UPMC Hillman Cancer Center is recruiting people with mesothelioma for a Phase 2 clinical trial testing autologous tumor infiltrating lymphocyte (TIL) cell therapy, led by principal investigator Udai S. Kammula.
The trial, designated NCT03935893, is enrolling at one site in Pennsylvania.
About the Study
This is a Phase 2 study evaluating a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in people with locally advanced, recurrent, or metastatic cancer, including mesothelioma. Other eligible cancer types include gastric or esophagogastric, colorectal, pancreatic, sarcoma, neuroendocrine, squamous cell, Merkel cell, and mismatch repair deficient or microsatellite unstable cancers. The primary endpoint is objective response rate (ORR).
Treatment Approach
This trial uses adoptive cell therapy with autologous tumor infiltrating lymphocytes (TIL) plus high-dose aldesleukin (IL-2), not checkpoint inhibitor immunotherapy.
Key trial details:
- Phase: Phase 2
- Sponsor: UPMC Hillman Cancer Center (PI: Udai S. Kammula)
- Intervention: Autologous TIL cell therapy with high-dose aldesleukin
- Status: Recruiting
Why This Trial Matters
Adoptive cell therapy with tumor infiltrating lymphocytes is an active area of research for solid tumors, including mesothelioma. This trial tests whether a patient’s own expanded T cells, combined with high-dose aldesleukin, can produce measurable responses in cancers that have exhausted standard therapy.
Study Locations
The trial is recruiting at:
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening